Diabetic foot ulcers in conjunction with lower limb lymphedema: pathophysiology and treatment procedures by Kanapathy, M et al.
© 2015 Kanapathy et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Chronic Wound Care Management and Research 2015:2 129–136
Chronic Wound Care Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
129
R e v i e W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CWCMR.S62919
Diabetic foot ulcers in conjunction with lower 
limb lymphedema: pathophysiology and  
treatment procedures
Muholan Kanapathy1
Mark J Portou1,2
Janice Tsui1,2
Toby Richards1,2
1Division of Surgery and 
interventional Science, University 
College London, 2Department of 
vascular Surgery, Royal Free London 
NHS Foundation Trust Hospital, 
London, UK
Correspondence: Mark J Portou 
Department of vascular Surgery, Royal 
Free London NHS Foundation Trust 
Hospital, London NW3 2QG, UK 
email mjportou@doctors.org.uk
Abstract: Diabetic foot ulcers (DFUs) are complex, chronic, and progressive wounds, and 
have a significant impact on morbidity, mortality, and quality of life. A particular aspect of 
DFU that has not been reviewed extensively thus far is its management in conjunction with 
peripheral limb edema. Peripheral limb edema is a feature of diabetes that has been identified 
as a significant risk factor for amputation in patients with DFU. Three major etiological factors 
in development of lymphedema with concurrent DFU are diabetic microangiopathy, failure 
of autonomic regulation, and recurrent infection. This review outlines the pathophysiology of 
lymphedema formation in patients with DFU and highlights the cellular and immune compo-
nents of impaired wound healing in lymphedematous DFU. We then discuss the principles of 
management of DFU in conjunction with lymphedema.
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Introduction
Globally, approximately 370 million people have diabetes and this number is on the 
rise.1 Diabetes UK estimates that by 2030, nearly 552 million people worldwide will 
have diabetes.2 In the UK alone, approximately 2% of the population is estimated to 
have diabetes, of which 15% will develop foot ulceration at some point in their lives.3 
Overall, 8% of hospital admissions involve patients with diabetes.
Diabetic foot ulcers (DFUs) are complex, chronic, and progressive wounds, and 
have a significant impact on morbidity, mortality, and quality of life.4,5 Diabetic patients 
have a 20-fold increased risk of amputation compared with non-diabetics, and DFU 
directly leads to 6,000 amputations per year in England alone.6 The prognosis often 
remains poor despite amputation. Historical data demonstrate 50% mortality at 2 years 
following major amputation,7 and an overall decrease in 5-year survival of 41%–70% 
has been reported.8 Even between diabetic populations, the presence of DFU represents 
an approximately 50% increased mortality risk.9
The economic burden of DFU management is significant. In the UK, an estimated 
£639–£662 million was spent in 2010–2011 on the management of DFU and subsequent 
amputation, representing 0.6%–0.7% of the entire National Health Service annual 
budget.6 In the USA, 33% of the $116 billion total health care spend on diabetes is on 
the management of foot ulceration.10
Peripheral limb edema is a feature of DFU and despite the lack of an estimate of 
its incidence or prevalence in DFU, it has been identified as a significant risk factor for 
amputation in patients with DFU.11,12 Diabetes, however, has been identified as a comor-
bidity in 23.5% of patients with lymphedema in a multicenter study of 1,000 patients 
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with chronic leg ulcers and is also reported to be a significant 
comorbidity in breast cancer survivors with lymphedema.13,14 
The resistance of diabetic ulcers to healing is undoubtedly 
multifactorial, but having concurrent lymphedema further 
impairs the wound healing process.11,12 This review outlines 
the pathophysiology of lymphedema formation in DFU and 
the principles of management of DFU in conjunction with 
lymphedema.
Pathophysiology of lymphedema 
formation in DFU
DFU has traditionally been linked to peripheral vascular 
disease, peripheral neuropathy, and infection.3 Peripheral vas-
cular disease is more common in patients with diabetes and is 
traditionally classified into macrovascular and microvascular 
complications. Neuropathy affects the motor, sensory, and 
autonomic nerves and their associated functions, with local 
trauma and pressure in the neuropathic foot being the lead-
ing factors in the development of DFU. Recurrent infection 
in the functionally immunosuppressed diabetic can have 
devastating sequelae.15
Lymphedema is a condition of localized fluid retention 
and tissue swelling caused by a compromised lymphatic 
system. Primary lymphedema develops as result of lym-
phatic abnormalities from congenital hypoplasia, aplasia, 
or valvular incompetence that could present at birth or later 
in life. Secondary lymphedema occurs due to recurrent 
infection and inflammation, parasitic infection, malignancy, 
trauma, or iatrogenic causes, resulting in failure to drain 
protein-rich lymphatic fluid from the interstitium, lead-
ing to edema of the affected site. Secondary lymphedema 
is seen in patients with lymphedematous DFU.
The pathophysiology of DFU in conjunction to lym-
phedema has not been widely discussed, although several 
studies have been undertaken to better understand the 
development of peripheral limb edema in diabetes. This 
section explores the pathophysiology of lymphedema in 
DFU, focusing on the three major underlying etiologies of 
DFU, ie, diabetic microangiopathy, failure of autonomic 
regulation, and recurrent infection. We then highlight the 
cellular and immune component of impaired wound healing 
in lymphedematous DFU.
Diabetic microangiopathy  
and lymphedema
The important role of hyperglycemia in the development 
and progression of microvascular complications has been 
clearly established.16 In the hyperglycemic state, abnormal 
glucose metabolism leads to production of advanced glycation 
end products. These, among other consequences, interfere 
with vascular remodeling, which has been proposed as a 
mechanism for development of diabetic microangiopathy.17 
Microangiopathy alters the structure and function of the 
microvasculature, leading to loss of the vascular barrier and 
tone regulation, resulting in increased capillary filtration of 
fluid into the tissues.17
When the capillary filtration rate exceeds the rate of 
lymphatic drainage, fluid accumulates in the intercellular 
space, leading to edema, which is governed by Starling’s 
principle of fluid exchange (equation 1). Starling’s principle 
states that fluid transport across the exchange vessel wall is 
driven by the hydraulic pressure gradient and opposed by 
the colloid osmotic pressure gradient between the plasma 
and the interstitium.18 In diabetic microangiopathy, the 
hydraulic conductance of the capillary wall (L
p
) is increased 
due to structural and functional impairment, resulting in an 
increased capillary filtration rate.
 Starling’s equilibrium: J
v
 = L
p
 S ([P
c
 – P
i
] – σ [π
p
 – π
i
])
 (1)
where J
v
 is the capillary filtration rate, L
p
 is the hydraulic 
conductance of the capillary wall, S is the surface area, P is 
the pressure within the capillary (c) or interstitium (i), σ is the 
osmotic reflection coefficient of the capillary wall, and π is 
the osmotic pressure of plasma (p) or interstitial fluid (i).
This is further exacerbated by the increased resting blood 
flow in the skin, the capillary filtration rate, and the hydro-
static pressure in the lower limbs compared with the upper 
limbs, leading to lower limb lymphedema.19–21
Microangiopathy also affects endothelial function with 
increased capillary permeability to large proteins and mol-
ecules in diabetic patients, a feature that can be seen by 
the transcapillary escape rate of radiolabelled albumin.22,23 
Removal and drainage of interstitial albumin appears to be 
delayed in diabetic patients, suggesting a defect in lymphatic 
function due to overflow saturation of the lymph pumps.22 
Hence, although diabetes does not cause direct damage to the 
lymphatic vessels, the processes of normal interstitial fluid 
homeostasis are affected with the increase in transport capac-
ity that overwhelms the drainage system. This has been dem-
onstrated by the improvement of edema and notable reduction 
in local capillary filtration with drugs acting on capillary 
permeability such as O-(beta-hydroxyethyl)-rutosides and 
Pycnogenol in subjects with diabetic microangiopathy.24–26 
Reduction in lymphedema was accompanied by improvement 
in ulcer healing.25
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Diabetic neuropathy and lymphedema
The pathogenesis of diabetic neuropathy is thought to involve 
disturbance in the metabolism and vasculature of nerve tissue 
due to excessive glucose uptake, leading to damage of periph-
eral nerves.27 The functional subunit in lymphatic vessels is 
the lymphangion, wall of which consists of smooth muscle 
cells that propel lymph in a peristaltic manner, contraction 
of which is under neural control.22 Analogous to the blood 
vessels, the peripheral lymphatic vessels and smooth muscle 
subunits are under autonomic control. Diabetic neuropathy 
can lead to lymphatic pump failure, impairing interstitial 
fluid uptake from the distal part of the limb and disrupting 
lymphatic fluid transport along the lymphatic vessels.22 The 
disorder in absorption and transport of lymphatic fluid is 
analogous to direct neural injury with sympathetic denerva-
tion interruption seen in trauma where management by com-
plex physical decongestion therapy with manual lymphatic 
drainage (MLD) results in clinical improvement.28
Recurrent infection and lymphedema
Patients with DFU are predisposed to recurrent wound infec-
tions, contributed to by the open wound and immunological 
perturbation. The shift in balance between the host defense 
system and bacterial load in the wound favors soft tissue 
infection which leads to destruction of host tissue. Recurrent 
soft tissue infection invariably damages the lymphatic system 
located in the dermal layer of the skin. The affected lym-
phatics become inflamed, dilated, and filled with exudate, 
chiefly neutrophils and monocytes. Abnormal accumula-
tion of interstitial fluid, proteins, growth factors and other 
active peptide moieties, glycosaminoglycans, and particulate 
matter also includes bacteria. The overload and failure of 
lymphatic intestinal drainage with accumulation of these 
larger elements leads to occlusion of the lymphatic system 
and stasis, providing an ideal microenvironment for bacterial 
growth, commonly group A β-hemolytic Streptococcus and 
Staphylococcus aureus.29–31 Accumulation of lymphatic fluid 
within the interstitium stimulates fibroblasts, keratinocytes, 
and adipocytes, leading to deposition of collagen and gly-
cosaminoglycans within the skin and subcutaneous tissue.31 
This is accompanied by chronic inflammation, involving 
lymphocytes, monocyte/macrophages, and dendritic cells. 
These inflammatory cells produce several inflammatory 
cytokines related to fibrosis, such as connective tissue growth 
factor, transforming growth factor-β, and platelet-derived 
growth factor, besides upregulating the cellular proliferation 
and migration of fibroblasts.31 The outcome of this is further 
soft tissue destruction, which exacerbates the lymphedema. 
Lymphatic dysfunction also impairs the local immune 
response, which plays a permissive role in propagation of 
bacterial and fungal invasion, further worsening the existing 
lymphatic dysfunction leading to a chronic state with reduced 
reversibility of the edema.31
Impaired wound healing  
in lymphedematous DFU
Wound healing is a complex physiological process involving 
numerous types of cells, growth factors, and cytokines, each 
of which is required at the correct time and for the appropriate 
duration. Impaired wound healing in the lymphedematous 
DFU is attributed to altered function at the cellular level, com-
pounded by the inflammatory reaction and impaired immune 
system. This section exemplifies the cellular and immunologi-
cal aspects of impaired wound healing in lymphedematous 
DFU through two important mechanistic processes of wound 
healing: the gap junctional protein and the Toll-like receptors 
(TLRs) of the innate immune system.
Cellular component in  
DFU and lymphedema
Accumulation of fluid in the interstitial space results in 
abnormal function at both the tissue and cellular level.32 The 
ensuing increase in physical distance between tissue chan-
nels can affect metabolic exchange, impairing the delivery 
of oxygen and nutrients and the discharge of toxins and 
inhibitory factors, with a resultant shift toward anaerobic 
metabolism. Likewise, the wider separation between cells 
affects the exchange of gases between plasma membranes. 
Given that the rich microvascular network in the skin is 
located in the papillary dermal layer, formation of interstitial 
edema that increases intercellular spaces affects oxygenation 
to the epidermal layer of the skin.33 This leads to alteration 
of the tissue properties in response to external pressure, 
predisposing to ulcer formation. This is particularly true in 
weight-bearing areas such as the plantar surface of the foot, 
which is the commonest location for DFU.33
Important transmembrane proteins involved in the pas-
sage of nutrients between cells and gaseous exchange are the 
connexin family of gap junctional proteins. Gap junctions are 
highly specialized structures, made up of channels spanning 
adjacent cell membranes, leaving a 2–4 nm extracellular 
“gap”, hence their name.34 These channels are assembled 
of transmembrane proteins called “connexins”, which are 
described in terms of molecular mass (Cx43 represents 
the connexin protein of 43 kDa). As the key mechanism of 
cellular communication, connexins are involved in epidermal 
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innate immunity, inflammation control, and wound repair.35 
A wide range of connexins are found within the skin (includ-
ing Cx26, 30, 30.3, 31.1, 32, 37, 40, 43, and 45), with Cx43 
being the most ubiquitous and found in dermal fibroblasts, 
blood vessels, and appendages such as sweat glands, seba-
ceous glands, hair follicles, mast cells, and activated leuko-
cytes, as well as epidermal keratinocytes.36,37 Connexins are 
associated with the pathogenesis of both type 1 and type 2 
diabetes, and are directly linked to wound healing. Abnormal 
upregulation of Cx43 seen in diabetic wounds binds cells 
together and prevents migration of keratinocytes from the 
wound edge, delaying re-epithelialization and the wound 
healing process.38,39 Preventing upregulation of Cx43 expres-
sion in a diabetic wound has been reported to increase the 
rate of re-epithelialization in a mouse model.40
Three connexin isoforms, Cx37, Cx43, and C47, have 
been shown to be involved in development and function of 
the lymphatics.41 Loss of function in knockout mice results 
in widely dilated superficial lymphatics in the skin and severe 
lymphedema due to complete absence of valve formation.41,42 
Mutation experiments on connexins, on the other hand, 
resulted in impaired uptake of lymphatic fluid without obvi-
ous anatomical defect involving the lymphatic vessels.43 Data 
suggest that coordinated function of gap junctions is needed 
to mediate the propagation of spontaneous contractions in 
the lymphatic vasculature.44 Although these in vivo studies 
have demonstrated the effect of deletion of connexin, it is 
still unknown if the changes in expression of connexin seen 
in chronic wounds affect lymphangiogenesis.
innate immune system in  
DFU and lymphedema
Persistent and excessive inflammation results in disruption of 
wound healing in diabetes. DFU become stalled in the inflam-
matory phase of wound healing, fails to progress, and a chronic 
ulcer results. This excessive “hyperinflammation” is mediated 
in part by the TLRs of the innate immune system. TLRs are 
key pattern recognition receptors of the innate immune system, 
which confer specificity to the innate immune system through 
recognition of discrete molecular patterns such as microbial cell 
wall constituents.45 Stimulation of TLRs results in activation of 
a variety of cell-dependent responses, including antigen pre-
sentation and activation of a potent pro-inflammatory cascade, 
with release of inflammatory cytokines, such as interleukin-6 
and tumor necrosis factor-α, and phagocytosis.46
In addition to exogenous microbial ligands known 
as pathogen-associated molecular patterns, TLRs also 
recognize endogenous “self ” patterns that are released in 
response to tissue damage, known as damage-associated 
molecular patterns (DAMPs).46 DAMPs act as danger 
signals triggered by tissue damage, and initiate a TLR-
mediated inflammatory response, that in turn alerts the 
immune system to the presence of tissue injury.47 Under 
normal circumstances, the resulting influx of inflamma-
tory cells and stimulates a sterile inflammatory reaction to 
control bacterial infection and remove debris. Activation 
of DAMP TLRs is regarded as essential for initiation of 
the wound healing process.48 However, in diabetes, con-
troversy exists as to whether TLR-mediated inflammation 
has a beneficial or inhibitory effect on wound healing.49 In 
animal studies, TLR2 and TLR4 inhibition or knock-out 
has a detrimental effect on the wound healing process for 
up to 7 days following injury, indicating the importance of 
TLR2 and TLR4 in the early phases of wound healing.50,51 
However, in diabetes-induced mice, TLR2 and TLR4 dele-
tion conferred an apparent protective effect, demonstrated 
by significantly improved wound healing and a reduction in 
the pro-inflammatory environment of the wound, compared 
with wild-type diabetic rodents.52,53
In lymphedema, DAMPs such as high-mobility group 
box 1 and heat-shock protein appear elevated in response to 
lymphatic stasis.54 Inhibition of high-mobility group box 1 
leads to a significant reduction in inflammatory lymphangio-
genesis, suggesting a negative role for DAMPs in promoting 
lymphangiogenesis besides provocating chronic inflamma-
tory response in chronic lymphedema.54 Studies in a mouse 
model of post-surgical lymphedema deficient for TLR2, 
TLR4, and TLR9 demonstrated significantly worse effects 
post injury compared with those in a wild-type model, as 
evidenced by increased tissue edema, reduced lymphangio-
genesis, increased fibrosis, and increased leucocyte infiltra-
tion but reduced monocyte infiltration.55 The data suggest a 
role for TLRs in the normal repair of lymphatic injury and 
resolution of lymphedema.55
Consequently, although TLRs appear to have a role in 
normal inflammation and swelling, their role in the diabetic 
patient with lymphedema may be confused, and the exces-
sive TLR-mediated inflammation associated with diabetes is 
counterproductive with resultant chronic lymphedema.
Principles of management
While the current standard of care for DFU is well established 
by clinical guidelines and pathways and a recent systematic 
review by Braun et al, there remains a lack of high-quality 
evidence on the management of DFU in conjunction with 
lymphedema.5,56
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Best practice management for DFU with or without 
lymphedema includes rapid assessment and correction 
where possible (or necessary) of macrovascular arterial 
insuff iciency. The importance of wound assessment, 
debridement and cleansing, recognition and treatment of 
infection, revascularization, and selection of an appropri-
ate dressing to achieve optimal healing is undeniable. 
However, managing DFU requires comprehensive attention 
with good diabetic control, offloading strategies, and an 
integrated approach to wound care.56 This section highlights 
the principles of management of DFU in conjunction with 
lymphedema.
Glycemic control
Evidence for the benefit of good glycemic control is well 
established.57 Randomized controlled trials (RCTs) such as 
the Diabetes Control and Complication Trial in type 1 dia-
betes demonstrated a significant reduction in development of 
microvascular complications such as retinopathy, nephropa-
thy, and microalbuminuria and in neurological complications 
such as neuropathy in the intensive therapy groups.16 The 
UK Prospective Diabetes Study in type 2 diabetes similarly 
demonstrated a significant reduction in “any diabetes related 
end-point”, progression of retinopathy, and microalbuminuria 
in the tightly controlled treatment arm, regardless of treat-
ment modality.16 While no studies have examined the effect 
of tight glycemic control on the development, progression, 
and treatment of lymphedema in DFU, it seems intuitive that 
a reduction in the risk of diabetes-related microangiopathic 
complications and in the secondary consequences of hyperg-
lycemia, such as cellulitis and other skin infections, through 
long-term close glycemic control will benefit the prevention 
and treatment of lymphedema.
Decongestion therapy
Decongestion therapies, including compression bandaging, 
MLD, and physical exercises, improve dermal lymphatic 
plexus lymph flow and have been the accepted non-surgical 
method to manage lymphedema.58 MLD involves special-
ized rhythmic pumping techniques to massage the affected 
area and enhance the flow of lymph from the peripheries 
toward the heart. This gentle skin massage encourages 
superficial lymphatic contraction, thereby increasing lymph 
drainage.59 Current imaging studies with near-infrared fluo-
rescence have demonstrated the positive effect of MLD in 
increasing lymphatic vessel contractility and lymph velocity, 
leading to resolution of clinical symptoms.60,61 The benefit 
of MLD in lymphedema secondary to complex regional 
pain syndrome, a clinical condition characterized by post-
traumatic diffuse pain with autonomic and vasomotor 
changes, indicates that MLD could also benefit edema due 
to autonomic impairment as seen in DFU.62 Conversely, a 
recent systematic review of the RCTs evaluating the effects 
of MLD on breast cancer-related secondary lymphedema 
indicates that MLD does not prevent or treat lymphedema.63 
However, there were clinical and statistical inconsistencies 
between the various studies, confounding the evaluation of 
the reviewed studies.63
Compression therapy has been advocated for the man-
agement of lymphedema and in the management of high 
perfusion microangiopathy in patients with DFU. Compres-
sion therapy with elastic stockings reduces capillary leakage 
and formation of edema, and may retard the progression of 
diabetic microangiopathy.64 Use of stiff, short-stretch ban-
dages with high working pressure and low resting pressure 
provides resistance to the accumulation of interstitial fluid 
while stimulating the rhythmic contraction of lymphatic col-
lectors during exercise.65 Working pressure is determined by 
the resistance provided by the bandage against the underly-
ing muscle contraction, while the pressure exerted on tissue 
at rest is the resting pressure.65 Two RCTs have shown that 
compression therapy with the use of intermittent pneumatic 
compression (IPC) is effective in reducing healing time for 
DFU in addition to reducing lymphedema.66,67 The mecha-
nism of action of IPC is believed to include enhancement of 
fibrinolysis and venous outflow, thereby reducing edema.67,68 
IPC simulates the effect of walking and weight-bearing 
on the venous system by the intermittent compression-
decompression cycle. However, compression therapy is 
limited in the presence of peripheral vascular disease. One 
RCT evaluated the effect of compressed air massage on the 
rate of diabetic ulcer healing, with all patients receiving 
standard medical and surgical treatment, while in addition, 
one group received air massage at 100 kPa for 15–20 minutes 
for 5 days per week. This study found a significant reduc-
tion in time to DFU healing, with an average time of 58.1 
days in patients (n=28) receiving compressed air massage, 
while those patients (n=27) receiving only standard wound 
care averaged 82.7 days until ulcer healing.66 Compressed 
air massage has been shown to significantly improve local 
skin blood flow measured using laser Doppler fluxmetry.66 
Another double-blind RCT compared healing at 12 weeks 
between a pulsatile pneumatic foot compression system with 
a bladder that inflates to 160 mmHg for 2 seconds to empty 
the veins of the foot, repeating the cycle every 20 seconds 
for 8 hours a day in 52 patients, against a non-functioning 
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foot compression device in 45 patients. This study found a 
significant increase in healing efficacy in patients with DFU,67 
along with a significant reduction in edema in the study arm 
receiving IPC therapy.
Limb offloading is a common strategy in the management 
of diabetic foot disease, and standard offloading devices are 
believed to reduce edema by enabling patients to remain 
relatively mobile; however, there are no objective published 
data confirming this.69 An alternative view is that immobiliza-
tion of the ankle reduces function of the calf muscle pump, 
impairing venous return, potentially resulting in increased 
foot edema.69
Surgical management
Surgical management of DFU with lymphedema can be 
divided into debridement, debulking, and a microsurgical 
approach. Wound debridement is considered part of standard 
DFU care. Debridement, the most important intervention 
for decreasing the risk of limb amputation in patients with 
DFU, involves the removal of callus and necrotic tissue, 
and reduction of bacterial biofilm.70 Debridement may be 
surgical, enzymatic (collagenase), autolytic (ie, occlusive), 
or biologic (larval). The different types of debridement for 
DFU, along with their advantages and disadvantages, have 
been recently reviewed by Yazdanpanah et al.71
Debulking surgery, such as the Charles procedure, which 
involves extensive excision of subcutaneous tissue followed 
by skin grafting, may be the simplest approach to reducing 
the volume of lymphedematous limbs but often results in 
substantial morbidity. Treatment of secondary lymphedema 
in the presence of DFU using the Charles procedure was 
described in a case report; however, it is an aggressive treat-
ment with a prolonged treatment course.72 The debulking 
procedure is particularly useful for ulcers with deep sinuses 
in the presence of chronic lymphedema where excision of 
the ulcer along with the sinus tract can be performed as a 
combined debulking procedure.73
Microsurgical techniques for treating lymphedema con-
sist of lymphovenous anastomosis and vascularized lymph 
node transfer. Lymphovenous anastomosis creates a detour 
route from the lymphatics to the vein at the peripheral 
region of the affected limb, thereby increasing lymphatic 
drainage. Lymphovenous anastomosis has minimal morbid-
ity; however, several studies have found that it is less effective 
in advanced-stage lymphedema, hence less likely to benefit 
patients with both lymphedema and DFU.74 Vascularized 
lymph node transfer, a relatively new surgical treatment 
for lymphedema, involves transfer of lymph nodes to the 
lymphedematous limbs followed by microanastomosis of 
blood vessels. Despite promising outcomes in the clinical 
setting, the interaction between the transferred lymph nodes 
and the lymphatic system in the transfer site is not yet well 
understood.74 Lahteenvuo et al and Honkonen et al showed 
that the transferred lymph nodes produce vascular endothe-
lial growth factor-C, inducing lymphangiogenesis which 
may facilitate canalization of recipient lymphatic vessels to 
the lymph node.75,76 Lin et al and Cheng et al hypothesized 
that the transferred lymph nodes act as “lymph pumps”, 
ejecting the absorbed lymph fluid from the surrounding inter-
stitial tissue into the venous circulation via the lymphovenous 
communication.77,78 Despite the encouraging results in treat-
ing lymphedema, the reported clinical studies involve only 
patients with chronic lymphedema secondary to iatrogenic 
injury, which does not reflect the exact pathophysiology 
of lymphedema associated with a DFU. Furthermore, the 
surgical complexity and potential morbidity at the donor 
site of vascularized lymph node transfer may complicate its 
application.
Conclusion
Foot ulceration represents a significant burden of morbidity 
and excess mortality for diabetic patients, and is an enormous 
challenge for health care providers. There is significant over-
lap in the pathophysiology of both DFU and lymphedema, 
but further research is needed to better our understanding. 
The treatment strategies outlined here address the manage-
ment of DFU in conjunction with lower limb lymphedema; 
however, novel strategies such as manipulation of innate 
immune inflammatory pathways through modulation of TLR 
and connexin regulation therapies have the potential to ben-
efit both these pathologies. Our understanding of lymphatic 
biology in relation to chronic ulcers has to be advanced with 
further research, as it holds immense benefit for both patients 
and the health care system.
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